SightGlass Vision, Inc.

Our medical device company is developing spectacle lenses to slow the progression of myopia (nearsightedness) in children.

[SightGlass Vision, Inc. @SightGlassVis]

Experiencing SightGlass Vision’s Spectacle Lenses - https://t.co/drvCkZMyU5

[SightGlass Vision, Inc. @SightGlassVis]

Excited to share this article from @PCONews about the growing #myopia epidemic and how our novel DOT spectacle lenses are designed to slow #myopia progression in children.
https://t.co/3ci3r236FD

[SightGlass Vision, Inc. @SightGlassVis]

Check out this article @MassDevice about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children.
https://t.co/jNWHqn1U4j

[SightGlass Vision, Inc. @SightGlassVis]

Thank you Review of #Myopia Management for this article about our CE Mark achievement for our novel DOT spectacles lenses for myopia management in children.
https://t.co/KoM7Evpmiz

[SightGlass Vision, Inc. @SightGlassVis]

Check out this @EyewireTV segment about our suite of novel DOT spectacle lenses designed to slow #myopia progress in children and achieving CE Mark allowing European Marketing Authorization. https://t.co/ehA1EtfOsV

[SightGlass Vision, Inc. @SightGlassVis]

Excited to share this article from #FierceBiotech about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children. https://t.co/yVupjqNDsw

[SightGlass Vision, Inc. @SightGlassVis]

Excited to share this https://t.co/e3quPqGbn2 article about #myopia that features @SightGlassVis and our novel DOT spectacle lenses.
https://t.co/coiMMPNn3B

[SightGlass Vision, Inc. @SightGlassVis]

Achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow the progression of #myopia in children is an important leap forward for our Company, as we advance our mission to end #myopia. https://t.co/CKswhMXoc2

[SightGlass Vision, Inc. @SightGlassVis]

We now have definitive data to show that our novel eyeglasses reduce the progression of nearsightedness in children. Check out this article in #Eyewire about our #CYPRESS pivotal trial topline data. https://t.co/FArE9do89o

[SightGlass Vision, Inc. @SightGlassVis]

Check out this Optometric Management article about our #CYPRESS pivotal trial in #myopia. Topline 1-yr results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline.

[SightGlass Vision, Inc. @SightGlassVis]

Excited to share this article from #Healio Primary Care Optometry News about topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. https://t.co/aSXyDfnIHU

[SightGlass Vision, Inc. @SightGlassVis]

Check out the topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. Results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline. https://t.co/WvxqkrX0D7

[SightGlass Vision, Inc. @SightGlassVis]

Thanks to Optical Journal https://t.co/UJ0OMkLN4H and Eyewire News https://t.co/6Uex5ux6jq for writing about the positive data from our #CYPRESS pivotal trial investigating our novel spectacle lenses for #myopia in children.

[SightGlass Vision, Inc. @SightGlassVis]

Check out the write up about our #CYPRESS pivotal trial investigating novel eyeglasses for #myopia in children in Review of Myopia Management https://t.co/EwJndDGx0F.

[SightGlass Vision, Inc. @SightGlassVis]

Excited to share this article from Optometric Management about our #CYPRESS pivotal trial of novel eyeglasses for #myopia in children.

[Eyecare Business Mag @eyecarebusiness]

.@SightGlassVis shared results from an interim analysis of the its trial evaluating its eyeglasses designed to slow the progression of #myopia in children. The clinical trial showed that both test arms demonstrated a reduction in myopia progression: https://t.co/HetcADoItf.

[SightGlass Vision, Inc. @SightGlassVis]

We're excited to announce that a planned interim analysis from our #CYPRESS pivotal clinical trial of novel eyeglasses designed to control #nearsightedness (#myopia) demonstrated successful reduction of myopia progression in children. Click here https://t.co/XTb6VPVwS0 for info

[SightGlass Vision, Inc. @SightGlassVis]

Check out Joe Rappon, OD, MS, FAAO, Chief Medical Officer at SightGlass Vision, on camera interview with Helio at the World Congress of Optometry 2019 #myopia

https://t.co/nreJbGtDwQ

[SightGlass Vision, Inc. @SightGlassVis]

#ICYMI: We presented data from our three studies overviewing discovery to clinical development of our novel lenses to control #myopia in children – PALM (pilot), WALNUT (preliminary), CYPRESS (pivotal) – at Academy 2019 & 3rd #WCOCongress19. https://t.co/xJ9n2ZKlPc.
#myopia

[SightGlass Vision, Inc. @SightGlassVis]

We look forward to presenting for the first time data that tell the whole story of our novel lenses to control nearsightedness in children – from concept to the clinic – at Academy 2019 & 3rd World Congress of Optometry. https://t.co/xJ9n2ZKlPc. #myopia #Academy19 #WCOCongress19